Improvement of Depression and Cognitive Impairment with Memantine Therapy in Patient with Neuropsychiatric Systemic Lupus Erythematosus: Evidence Based Case Report
Abstract
Background: Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease that affects multiple organs. SLE can manifest neuropsychiatrically (NPSLE) with symptoms such as cognitive impairment, seizures, hallucinations, depression, and anxiety. Memantine is an NMDAR antagonist known to be effective as a treatment for cognitive disorders in dementia. Objective: To determine whether Memantine therapy can be administered for depression and cognitive impairment caused by autoimmune-related etiologies such as SLE. Methods: A systematic review of scientific evidence was conducted using an evidence-based approach. The search was performed on reliable databases, including PubMed, Cochrane, Scholar, Springer, and Medscape, using The Boolean Operator method. The keywords used were Cognitive Impairment, Cognitive Disorder, Dementia, Depression, Organic Depression, Memantine, Systemic Lupus Erythematosus, with filters set for publications from the last 15 years, human subjects, and English-language studies. Results: Three studies aligned with the clinical question. Study 1, conducted by Vidyanti et al., reported significant improvements in autoimmune dementia with the administration of Memantine at 10 mg. Study 2, by Czarnecka et al., reviewed Memantine's use in psychiatric conditions such as depression and schizophrenia and found supporting literature. Study 3, by Petri et al., reported improvements in several cognitive aspects in neuropsychiatric SLE. Conclusion: Evidence suggests that Memantine administration can improve cognitive impairment and depression in patients with NPSLE.
Keywords: Cognitive Impairment, Depression, Memantine, Systemic Lupus Erythematosus

